Drugs that contain Fish Oil Triglycerides

1. List of Omegaven drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350186 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Nov, 2024

(1 year, 8 months from now)

US9629821 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(2 years from now)

US9566260 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 27, 2023
Orphan Drug Exclusivity (ODE) Jul 27, 2025

NCE-1 date: July, 2022

Market Authorisation Date: 27 July, 2018

Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12; Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease; Treatment of liver disease through nutrition for patients under the age of 12

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in